$QTTB
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Paul Alloway
CEO
7
Employees
$11.66
Current Price
$3.02M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 2 | 4 | $30,000,000.00 | 3,750,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 2 | 4 | $30,000,000.00 | 3,750,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 4 | $30,000,000.00 | 3,750,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 4 | $30,000,000.00 | 3,750,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 28, 2026 | Xu Diyong Director | Purchase | 625,000 | $8.00 | $5,000,000.00 | View Details |
| May 28, 2026 | Xu Diyong Director | Purchase | 1,250,000 | $8.00 | $10,000,000.00 | View Details |
| May 28, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,250,000 | $8.00 | $10,000,000.00 | View Details |
| May 28, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 625,000 | $8.00 | $5,000,000.00 | View Details |
8 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.86
Actual$3.65
Beat
Revenue
EstimatedN/A
Actual$53.74M
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$TRAW โ Traws Pharma, Inc.via ORBIMED ADVISORS LLC$PRLD โ Prelude Therapeutics Incvia ORBIMED ADVISORS LLC$STTK โ Shattuck Labs, Inc.via ORBIMED ADVISORS LLC$EWTX โ Edgewise Therapeutics, Inc.via ORBIMED ADVISORS LLC$ACET โ Adicet Bio, Inc.via ORBIMED ADVISORS LLC$MBX โ MBX Biosciences, Inc.via ORBIMED ADVISORS LLC$SION โ Sionna Therapeutics, Inc.via ORBIMED ADVISORS LLC